Vertex Pharmaceuticals

VRTX

Market cap $112B

NextEra Energy operates the largest electric utility in the U.S. Vertex Pharmaceuticals markets therapies for treating cystic fibrosis and other diseases. Walmart is the world's largest consumer staples company and has a thriving e-commerce business.

The Undercovered Dozen series spotlights 12 lesser-covered stocks from the past week on Seeking Alpha. This week's edition covers articles published between March 27 and April 2, offering fresh investment ideas. The focus is on stocks that may offer unique opportunities due to limited analyst coverage.

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $443.92, signifying a +2.79% move from its prior day's close.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast can be.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.75, moving 1.9% from the previous trading session.

Vertex Pharmaceuticals (VRTX) remains a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA. VRTX's new label expansions now cover 95% of U.S. CF patients, adding 800 eligible patients and supporting continued revenue growth. Positive phase 3 data for povetacicept in IgAN and ongoing regulatory submissions position VRTX for further diversification beyond CF.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FD.

Multiple headwinds could bring the bull market to a halt. Stocks positioned to rise even during a market downturn include Berkshire Hathaway, Enbridge, and Vertex Pharmaceuticals.

One is a diversified healthcare giant with a vast product lineup and an impressive dividend program. The other is a niche leader with a lineup and pipeline that should help it perform well through 2046.